Hologic has received Emergency Use Authorisation (EUA) from the US Food and Drug Administration (FDA) for its Aptima SARS-CoV-2 assay.
The antigen test runs on Hologic’s fully automated Panther system, which can provide initial results within three hours and carry out over 1,000 Covid-19 tests within a 24-hour period.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The test was the first Covid-19 diagnostic to receive R&D support from the US government Biomedical Advanced Research and Development Authority (BARDA), receiving nearly $700,000 in funding.
Hologic plans to register its Aptima SARS-CoV-2 assay for a CE Mark for diagnostic use in Europe later in May.
